VaxGen, Inc. company was founded in 1995 and is based in South San Francisco, California. VaxGen, Inc., (VaxGen) is a biopharmaceutical company. VaxGen is focused on the development, manufacture and commercialization of biologic products for the treatment of human disease. The Company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. The Company has ended all product development activities and sold or otherwise terminated its drug development programs. On March 28, 2008, the Company entered into a Termination of Merger Agreement, Acknowledgment and Amendment to Loan Agreement and Secured Promissory Note, or Termination Agreement and Amendment, terminating immediately the Merger Agreement and amending the terms of VaxGen’s bridge loan to Raven.

GlaxoSmithKline Pharmaceuticals (GSK India) is the top of the pill heap. India's leading pharmaceutical manufacturer, the company makes pharmaceuticals and consumer health care products through its two manufacturing facilities in Nashik and Thane; it also has a clinical development center in Bangalore. Its products include those targeting problems with infections, gynecology, dermatology, diabetes, and the cardiovascular system. Top sellers are Augmentin, Zinetac, Calpol, Phexin, and Betnesol. GSK India also makes vaccines to treat or prevent hepatitis A and B, the flu, chickenpox, and tetanus. Its distribution network stretches throughout the country. UK-based drugmaker GlaxoSmithKline owns GSK India.

Allon Therapeutics Inc. company's primary focus is on developing treatments for Alzheimer's and other neurodegenerative diseases that lead to memory loss and cognitive impairment. Its lead candidate AL-108 is a nasal spray that has shown some efficacy in clinical trials in treating the symptoms of patients with amnestic mild cognitive impairment, a precursor to Alzheimer's. Allon has collaborations with the National Institute on Aging, the Alzheimer's Disease Cooperative Study, the Institute for the Study of Aging, and the Tel Aviv University.

Immtech Pharmaceuticals, Inc. company was founded in 1984 and is based in New York, New York. mmtech Pharmaceuticals, Inc. focuses on the discovery and development of drugs to treat infectious diseases worldwide. The company involves in drug discovery and development programs for hepatitis C and malaria; and provides aromatic cationic pharmaceutical compounds. It also offers assistance to healthcare companies seeking to conduct clinical trials, and manufacture and/or distribute pharmaceutical products in China. In addition, the company involves in investing in metal and mineral assets, primarily tin assets in China.

Innovative work in genetic testing is apparently spelled Innogenetics in any language. The biopharmaceutical company creates genetic, infectious disease, cancer, and neurological tests. Innogenetics' products include tests and genotyping profiles to identify conditions such as cystic fibrosis, HIV, hepatitis C and B, Alzheimer's disease, and human papillomavirus (HPV). In addition to testing, the company provides biological manufacturing services (producing virus strains and proteins) for pharmaceutical firms and research labs. The firm's products are sold through subsidiaries and distributors in about 90 countries. Belgium's Solvay took over control of Innogenetics in 2008.

Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

Formatech provides contract development services for pharmaceutical companies, including cell culture and fermentation, pre-formulation, dosage form, and purification development services. Its dosage forms include liquid, controlled release, tablets, capsules as well as topicals, such as gels, ointments, and creams. It also provides project management services to its contract development customers. The company also offers manufacturing services, such as aseptic fill, finishing, and lyophilization. Formatech's specializations include small molecules, vaccines, and monoclonal antibodies.

The Whitehead Institute for Biomedical Research blazes new trails in bioscience. The organization, funded by both the public and private sectors, investigates such diseases as Parkinson's and cancer and dives into the depths of biology, genomics, and genetics to gain new understanding about disease and health. The Whitehead Institute contributed to the international effort to map the human genome, and is actively researching stem cells. Other achievements include discovering a system for multiplying adult stem cells and creating the first genetically defined human cancer cell. The institute was founded in 1982 by philanthropist Edwin "Jack" Whitehead and draws researchers from MIT.

CSL Behring is among the world's largest fully integrated plasma collection companies. Through subsidiary CSL Plasma (formerly ZLB Plasma), the company collects plasma through dozens of facilities in the US and Germany. CSL Behring also develops plasma protein biotherapeutics to treat a range of health ailments, including bleeding disorders (such as hemophilia), immune system deficiencies, and respiratory disease (including emphysema). Biotherapeutics are also used in critical care settings for surgical and wound healing applications. CSL Behring is a subsidiary of Australian biopharmaceutical firm CSL Limited.

Metabasis Therapeutics, Inc. company was founded in 1997 and is based in La Jolla, California. Metabasis Therapeutics, Inc. (Metabasis) is a biopharmaceutical company focused on the discovery development of drugs. The Company’s product pipeline includes product candidates and advanced discovery programs for the treatment of metabolic diseases such as diabetes and hyperlipidemia, which it refer to as its core assets, as well as product candidates and advanced discovery programs for the treatment of liver diseases such as hepatitis and primary liver cancer, which it refer to as its non-core assets. All of its product candidates were developed internally using its HepDirect technology. The Company’s pipeline of clinical-stage product candidates also consists of its core asset, MB07803, a product candidate for the treatment of type 2 diabetes, and its non-core assets, pradefovir and MB07133, developed for the treatment of hepatitis B and primary liver cancer, respectively.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.